Emergent BioSolutions (NYSE:EBS) Shares Up 3.2% - Here's What Happened

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) traded up 3.2% during mid-day trading on Monday . The company traded as high as $9.74 and last traded at $9.65. 525,477 shares traded hands during trading, a decline of 85% from the average session volume of 3,530,859 shares. The stock had previously closed at $9.35.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on EBS shares. Rodman & Renshaw reaffirmed a "buy" rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reaffirmed a "buy" rating and set a $8.00 target price on shares of Emergent BioSolutions in a report on Friday, August 16th.

Emergent BioSolutions Price Performance

The stock has a market capitalization of $534.50 million, a PE ratio of -0.93 and a beta of 1.59. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06 and a quick ratio of 0.54. The stock's fifty day moving average is $8.38 and its 200-day moving average is $7.09.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The firm had revenue of $254.70 million for the quarter, compared to analysts' expectations of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same period in the previous year, the company earned ($1.06) earnings per share. As a group, equities analysts predict that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EBS. Susquehanna Fundamental Investments LLC purchased a new stake in Emergent BioSolutions in the 1st quarter worth $300,000. BNP Paribas Financial Markets increased its stake in shares of Emergent BioSolutions by 155.3% during the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company's stock worth $414,000 after purchasing an additional 99,520 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company's stock worth $1,864,000 after purchasing an additional 253,960 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Emergent BioSolutions during the 1st quarter worth about $57,000. Finally, Vanguard Group Inc. lifted its stake in Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company's stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.